Enlicitide: The First ORAL PCSK9 Inhibitor for Cholesterol

September 2026

You’ll hear that enlicitide (Lipfendra) is a game changer for managing high cholesterol...as the first ORAL PCSK9 inhibitor.

Enlicitide 20 mg once daily lowers LDL-C by about 60% when added to a statin in adults with high cholesterol...with or without ASCVD.

This is similar to injectable PCSK9 inhibitors (alirocumab, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote